BR112013000107A2 - aminopirazoloquinazolinas - Google Patents
aminopirazoloquinazolinasInfo
- Publication number
- BR112013000107A2 BR112013000107A2 BR112013000107A BR112013000107A BR112013000107A2 BR 112013000107 A2 BR112013000107 A2 BR 112013000107A2 BR 112013000107 A BR112013000107 A BR 112013000107A BR 112013000107 A BR112013000107 A BR 112013000107A BR 112013000107 A2 BR112013000107 A2 BR 112013000107A2
- Authority
- BR
- Brazil
- Prior art keywords
- aminopyrazoloquinazolines
- compounds
- medicaments
- excessive
- groups
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
- C07D493/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
aminopirazoloquinazolinas. a presente invenção refere-se a compostos de fórmula geral (i) em que os grupos r^ 1^ a r^ 3^ e x são definidos como na reivindicação 1, que são adequados para o tratamento de doenças caracterizadas por proliferação de célula excessiva ou anormal, preparações farmacêuticas que contêm tais compostos e o seu como medicamentos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10170683 | 2010-07-23 | ||
PCT/EP2011/062683 WO2012010704A1 (en) | 2010-07-23 | 2011-07-22 | New aminopyrazoloquinazolines |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112013000107A2 true BR112013000107A2 (pt) | 2016-05-17 |
Family
ID=43037625
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013000107A BR112013000107A2 (pt) | 2010-07-23 | 2011-07-22 | aminopirazoloquinazolinas |
Country Status (22)
Country | Link |
---|---|
US (1) | US8735386B2 (pt) |
EP (1) | EP2595987B1 (pt) |
JP (1) | JP5991974B2 (pt) |
KR (1) | KR20130132394A (pt) |
CN (1) | CN103097388A (pt) |
AP (1) | AP2012006640A0 (pt) |
AR (1) | AR082850A1 (pt) |
AU (1) | AU2011281504A1 (pt) |
BR (1) | BR112013000107A2 (pt) |
CA (1) | CA2803467A1 (pt) |
CL (1) | CL2012003745A1 (pt) |
CO (1) | CO6670575A2 (pt) |
EA (1) | EA201201661A1 (pt) |
EC (1) | ECSP13012448A (pt) |
GE (1) | GEP20156289B (pt) |
MA (1) | MA34389B1 (pt) |
MX (1) | MX2013000821A (pt) |
PE (1) | PE20131143A1 (pt) |
SG (1) | SG187548A1 (pt) |
TW (1) | TW201217380A (pt) |
UY (1) | UY33526A (pt) |
WO (1) | WO2012010704A1 (pt) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013110585A1 (en) | 2012-01-23 | 2013-08-01 | Boehringer Ingelheim International Gmbh | 5, 8 -dihydro- 6h- pyrazolo [3, 4 -h] quinazolines as igf-lr/lr inhibitors |
US9376437B2 (en) | 2013-03-13 | 2016-06-28 | Oncoceutics, Inc | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy |
AU2014349150B2 (en) * | 2013-11-15 | 2019-11-07 | Oncoceutics, Inc. | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, salts thereof and methods of use |
SI3250208T1 (sl) | 2015-01-30 | 2021-01-29 | Oncoceutics, Inc. | 7-benzil-4-(4-(trifluorometil)benzil)-1,2,6,7,8,9-heksahidroimidazo (1,2-A)pirido(3,4-E)pirimidin-5-(4H)-on in njegove soli ter njihova uporaba v terapiji |
JP6664414B2 (ja) * | 2015-05-13 | 2020-03-13 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | IGF−1R/IR阻害薬としての新規5,8−ジメチル−9−フェニル−5,8−ジヒドロ−6H−ピラゾロ[3,4−h]キナゾリン−2−イル)−(1H−ピラゾール−3−イル)−アミン及び誘導体 |
AU2017356569B2 (en) * | 2016-11-11 | 2020-10-08 | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | Pyridylamino substituted heterotricyclic compounds, and preparation method and pharmaceutical use thereof |
CN108484600B (zh) * | 2017-05-26 | 2022-12-13 | 江苏新元素医药科技有限公司 | 促尿酸排泄的urat1抑制剂 |
CN107383019B (zh) * | 2017-07-28 | 2019-10-15 | 江苏艾凡生物医药有限公司 | 吡唑并[4,3-h]喹唑啉类化合物及其用途 |
WO2019206154A1 (zh) | 2018-04-24 | 2019-10-31 | 上海海雁医药科技有限公司 | Cdk4/6抑制剂及其药学上可接受的盐和多晶型物及其应用 |
US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
CA3128200A1 (en) * | 2019-01-30 | 2020-08-06 | Yale University | Compounds, compositions, and methods for treating fibrosis |
WO2020168197A1 (en) | 2019-02-15 | 2020-08-20 | Incyte Corporation | Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors |
US11472791B2 (en) | 2019-03-05 | 2022-10-18 | Incyte Corporation | Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors |
MX2021010669A (es) * | 2019-03-07 | 2021-09-28 | BioNTech SE | Proceso para la preparacion de una imidazoquinolina sustituida. |
US11919904B2 (en) | 2019-03-29 | 2024-03-05 | Incyte Corporation | Sulfonylamide compounds as CDK2 inhibitors |
JP2022531094A (ja) * | 2019-04-19 | 2022-07-06 | ファウント バイオ, インコーポレイテッド | 皮膚内への活性剤の送達および保持 |
US11440914B2 (en) | 2019-05-01 | 2022-09-13 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
WO2020223558A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | Tricyclic amine compounds as cdk2 inhibitors |
AR119765A1 (es) | 2019-08-14 | 2022-01-12 | Incyte Corp | Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2 |
WO2021072232A1 (en) | 2019-10-11 | 2021-04-15 | Incyte Corporation | Bicyclic amines as cdk2 inhibitors |
KR20230035031A (ko) | 2020-06-05 | 2023-03-10 | 킨네이트 바이오파마 인크. | 섬유아세포 성장 인자 수용체 키나아제의 억제제 |
CN111960974A (zh) * | 2020-08-28 | 2020-11-20 | 山东潍坊润丰化工股份有限公司 | 一种烯草酮中间体的合成方法 |
CN116761806A (zh) * | 2021-02-08 | 2023-09-15 | 南京明德新药研发有限公司 | 5,6-二氢噻吩并[3,4-h]喹唑啉类化合物 |
US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3071830B2 (ja) * | 1995-10-02 | 2000-07-31 | エフ・ホフマン−ラ ロシュ アーゲー | 5ht2c受容体アンタゴニストとしてのピリミジン誘導体 |
OA13170A (en) | 2003-05-22 | 2006-12-13 | Pharmacia Italia Spa | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors. |
CN1897950A (zh) | 2003-10-14 | 2007-01-17 | 惠氏公司 | 稠合芳基和杂芳基衍生物及其使用方法 |
-
2011
- 2011-07-20 US US13/187,100 patent/US8735386B2/en active Active
- 2011-07-21 UY UY0001033526A patent/UY33526A/es not_active Application Discontinuation
- 2011-07-22 EP EP11734158.6A patent/EP2595987B1/en active Active
- 2011-07-22 KR KR1020137003430A patent/KR20130132394A/ko not_active Application Discontinuation
- 2011-07-22 CA CA2803467A patent/CA2803467A1/en not_active Abandoned
- 2011-07-22 WO PCT/EP2011/062683 patent/WO2012010704A1/en active Application Filing
- 2011-07-22 BR BR112013000107A patent/BR112013000107A2/pt not_active IP Right Cessation
- 2011-07-22 AR ARP110102670A patent/AR082850A1/es unknown
- 2011-07-22 MA MA35577A patent/MA34389B1/fr unknown
- 2011-07-22 TW TW100126062A patent/TW201217380A/zh unknown
- 2011-07-22 CN CN201180043930XA patent/CN103097388A/zh active Pending
- 2011-07-22 AP AP2012006640A patent/AP2012006640A0/xx unknown
- 2011-07-22 EA EA201201661A patent/EA201201661A1/ru unknown
- 2011-07-22 GE GEAP201113008A patent/GEP20156289B/en unknown
- 2011-07-22 AU AU2011281504A patent/AU2011281504A1/en not_active Abandoned
- 2011-07-22 JP JP2013520164A patent/JP5991974B2/ja active Active
- 2011-07-22 PE PE2013000125A patent/PE20131143A1/es not_active Application Discontinuation
- 2011-07-22 MX MX2013000821A patent/MX2013000821A/es active IP Right Grant
- 2011-07-22 SG SG2013003645A patent/SG187548A1/en unknown
-
2012
- 2012-12-28 CL CL2012003745A patent/CL2012003745A1/es unknown
-
2013
- 2013-01-22 CO CO13011464A patent/CO6670575A2/es active IP Right Grant
- 2013-02-19 EC ECSP13012448 patent/ECSP13012448A/es unknown
Also Published As
Publication number | Publication date |
---|---|
US8735386B2 (en) | 2014-05-27 |
EP2595987A1 (en) | 2013-05-29 |
CL2012003745A1 (es) | 2013-05-31 |
SG187548A1 (en) | 2013-03-28 |
WO2012010704A1 (en) | 2012-01-26 |
AU2011281504A1 (en) | 2013-01-10 |
UY33526A (es) | 2012-02-29 |
ECSP13012448A (es) | 2013-03-28 |
JP5991974B2 (ja) | 2016-09-14 |
MA34389B1 (fr) | 2013-07-03 |
KR20130132394A (ko) | 2013-12-04 |
EP2595987B1 (en) | 2018-04-18 |
TW201217380A (en) | 2012-05-01 |
PE20131143A1 (es) | 2013-10-23 |
AR082850A1 (es) | 2013-01-16 |
US20120238542A1 (en) | 2012-09-20 |
CN103097388A (zh) | 2013-05-08 |
EA201201661A1 (ru) | 2013-07-30 |
GEP20156289B (en) | 2015-05-25 |
CO6670575A2 (es) | 2013-05-15 |
JP2013532652A (ja) | 2013-08-19 |
CA2803467A1 (en) | 2012-01-26 |
AP2012006640A0 (en) | 2012-12-31 |
MX2013000821A (es) | 2013-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112013000107A2 (pt) | aminopirazoloquinazolinas | |
BR112015011158A2 (pt) | triazolopirazina | |
BR112013019714A2 (pt) | azaindolilfenil sulfonamidas como inibidores de serina/treonina quinase | |
CY1118859T1 (el) | 6-αλκινυλο-πυριδινες ως μιμητες smac | |
PH12015501385A1 (en) | Autotaxin inhibitors | |
BR112012027034A2 (pt) | inibidores da arginase e suas aplicações terapêuticas | |
BR112012027062B8 (pt) | composto, processo para a preparação de um composto e usos do mesmo | |
UY33817A (es) | ?nuevas oxindolpirimidinas bencílicas?. | |
BR112015001759A8 (pt) | agentes de modulação de atx, seus usos e composição farmacêutica | |
BR112013003864A2 (pt) | compostos de pirrolpirimidina e usos dos mesmos | |
BR112014010576A2 (pt) | inibidores de neprilisina | |
ECSP13013048A (es) | Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores | |
BR112013006344A2 (pt) | lactamas substituídas por piperdinila como moduladores de gpr119, composição farmacêutica as compreendendo, uso e processso para preparação das mesmas | |
CO6470899A2 (es) | 2,4-diaminopirimidinas para el tratamiento de enfermedades caracterizadas por proliferación celular excesiva o normal | |
UY35711A (es) | Bis-amidopiridinas como moduladores de la actividad de iap y sus usos como miméticos de smac | |
BR112015003729A2 (pt) | composto de fórmula estrutural i; composição farmacêutica; método de tratamento de uma doença mediada por caminho do hif; método de tratamento de uma doença causada por proliferação anormal de células; e método para alcançar um efeito em um paciente | |
BR112015000011A2 (pt) | compostos de triazol como medicamentos antivirais | |
BR112012018098A2 (pt) | compostos de 4-fenoxi-nicotinamida ou 4-fenoxi-pirimidina -5-carboxamida | |
BR112013030264A2 (pt) | ácidos acéticos de benzociclohepteno | |
BR112014008616A2 (pt) | compostos antivirais | |
BR112012017393A2 (pt) | derivados de 2,5,7-oxazolpirimidina substituída | |
BR112012014463A2 (pt) | ativadores de glucoquinase azaindol | |
BR112013003675A2 (pt) | compostos com atividade anticteriana contra clostridium | |
BR112012032235A2 (pt) | 3-oxo-3,9-diidro-1h-cromeno[2,3-c]pirróis como ativadores de glicoquinase | |
BR112015014145A2 (pt) | compostos antibacterianos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2373 DE 28-06-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |